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Metabolic Effects of Acute Thiamine Depletion Are
Reversed by Rapamycin in Breast and Leukemia Cells
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Abstract
Thiamine-dependent enzymes (TDEs) control metabolic pathways that are frequently altered in cancer and therefore
present cancer-relevant targets. We have previously shown that the recombinant enzyme thiaminase cleaves and depletes
intracellular thiamine, has growth inhibitory activity against leukemia and breast cancer cell lines, and that its growth
inhibitory effects were reversed in leukemia cell lines by rapamycin. Now, we first show further evidence of thiaminase
therapeutic potential by demonstrating its activity against breast and leukemia xenografts, and against a primary leukemia
xenograft. We therefore further explored the metabolic effects of thiaminase in combination with rapamycin in leukemia
and breast cell lines. Thiaminase decreased oxygen consumption rate and increased extracellular acidification rate,
consistent with the inhibitory effect of acute thiamine depletion on the activity of the TDEs pyruvate dehydrogenase and 2oxoglutarate dehydrogenase complexes; these effects were reversed by rapamycin. Metabolomic studies demonstrated
intracellular thiamine depletion and the presence of the thiazole cleavage product in thiaminase-treated cells, providing
validation of the experimental procedures. Accumulation of ribose and ribulose in both cell lines support the thiaminasemediated suppression of the TDE transketolase. Interestingly, thiaminase suppression of another TDE, branched chain
amino ketoacid dehydrogenase (BCKDH), showed very different patterns in the two cell lines: in RS4 leukemia cells it led to
an increase in BCKDH substrates, and in MCF-7 breast cancer cells it led to a decrease in BCKDH products. Immunoblot
analyses showed corresponding differences in expression of BCKDH pathway enzymes, and partial protection of thiaminase
growth inhibition by gabapentin indicated that BCKDH inhibition may be a mechanism of thiaminase-mediated toxicity.
Surprisingly, most of thiaminase-mediated metabolomic effects were also reversed by rapamycin. Thus, these studies
demonstrate that acute intracellular thiamine depletion by recombinant thiaminase results in metabolic changes in
thiamine-dependent metabolism, and demonstrate a previously unrecognized role of mTOR signaling in the regulation of
thiamine-dependent metabolism.
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lular folates only transiently associate with enzymes during the
catalytic process, allowing for inhibition of enzyme activity by
molecules designed to bind more tightly than the intracellular
substrates. In contrast, intracellular thiamine, activated by
phosphorylation, remains tightly bound to enzyme complexes
during the catalytic cycle, leaving little opportunity for inhibitors
to displace it once the complex has assembled. This inherent
pharmacologic challenge could disguise the potential of targeting
TDEs for cancer therapy.
We have previously shown down-regulation of thiamine
transporter gene expression in tumors compared to normal tissues
[2,3] and more recently have shown that a low thiamine diet
delays onset of mammary tumors in MMTV(her2) mice [4], an
effect that is abrogated by a high fat diet. These observations have
led to our hypothesis that TDE pathways are altered as part of the
overall changes in energy metabolism that occurs in cancer cells,

Introduction
Thiamine (vitamin B1) is a cofactor for enzymes involved in
critical metabolic processes involving energy production, biomass
generation and amino acid catabolism. Despite the requirement
for this vitamin in these central processes, the role of thiamine and
thiamine-dependent enzymes (TDEs) in cancer development and
treatment has received little attention, although a recent review
has summarized the potential importance of TDE’s in cancer
metabolism [1]. Unlike antifolates, which have a well-established
role in cancer therapy, analogous small molecule thiamine
antagonists are relatively inert, leading to a conclusion that TDE
pathways could not be important as an anticancer targets.
However, the limitations of small molecule TDE inhibitors should
not be confused with the potential role of TDEs as anticancer
therapeutic targets. Antifolates can be effective because intracel-
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well as flow cytometric analyses using Annexin-V labeling as
previously described [9].

and that these changes could produce metabolic vulnerabilities
that could be exploited by therapies aimed at TDE activities. To
take a novel path in the exploration of TDEs in cancer, we have
studied the cytotoxic activity of the bacterial enzyme thiaminase,
which cleaves thiamine into its pyrimidine and thiazole moieties
[5]. Thiaminase overcomes the limitations of small molecule TDE
inhibitors by causing immediate and nearly complete intracellular
and extracellular thiamine deprivation [6]. In previous studies we
have shown that thiaminase has both in vitro and in vivo cytotoxicity
activity, further supporting the concept that TDEs could represent
new targets for novel therapies [6,7,8]. We have also previously
reported that rapamycin has antagonistic effect on thiaminasemediated growth inhibition of leukemia cells [7], a surprising
finding since rapamycin generally acts as a sensitizing agent in
combination with cytotoxic drugs.
We now present metabolic and metabolomic observations
regarding the anticancer activities and metabolic effects of
thiaminase in leukemia and breast cancer cells. We chose to focus
on breast and leukemia models because these were the models in
which we observed the most promising activity of thiaminase in
xenografts. These studies help define thiaminase metabolic effects
that may be responsible for its cytotoxic activity. These studies also
further elucidate the role of mTOR as an inhibitor of thiaminasemediated alterations in cellular metabolism, and demonstrate the
role of mTOR in regulating expression of enzymes involved in
thiamine-dependent metabolism.

Xenograft studies
RS4 tumor xenografts were established by subcutaneously
inoculating 16107 cells into the right flank of five-week-old female
Crl:NU-Foxn1 nude mice (Charles River Laboratories, Wilmington, MA). For the establishment of MCF-7 xenograft, a 17bestradiol pellet (0.72 mg, 60 days release; Innovative Research of
America, Sarasota, FL) was implanted subcutaneously into the
neck to facilitate optimal tumor growth for the estrogen receptor–
positive MCF-7 cells. The xenografts were initiated by subcutaneously injecting 56106 MCF-7 cells into the right flank of fiveweek-old female Crl:NU-Foxn1 nude mice. When palpable
tumors had formed, mice were treated with native thiaminase at
its MTD (2000 units/kg body weight) twice a week at a site distant
from the formed tumor for three weeks. Mice were treated with a
single dose of thiaminase enzyme conjugated with 1k linear chain
PEG (1K-LCPTE) at its MTD (50 U/kg) at a site distant from the
formed tumor. Mice treated with N3-pyridyl thiamine (N3PT)
received an intraperitoneal (i.p.) dosage of 80 mg/kg daily for five
days. Mice treated with both 1K-LCPTE and N3PT received a
single dose of 1K-LCPTE at 50 U/kg first, then after 5five days,
mice received N3PT at 80 mg/kg daily for five days. Tumors were
measured twice a week in a blinded manner by measuring
perpendicular diameters with a digital caliper and tumor volumes
(mm3) were calculated using the following formula: volume =
width 6 width 6 length 6 p/6. The predetermined endpoint was
a tumor volume of 1500 mm3. The control mice were injected
with MCF-7 or RS4 cells and left untreated, and results combined
with a previous control group of the same xenograft [7]. KaplanMeier survival curves and statistical analysis was performed with
GraphPad Prism software.

Methods
Ethics statement
All animal studies were approved by the University of Kentucky
Institutional Animal Care and Use Committee.

Cell Lines
Primary lymphoblastic leukemia xenograft methods

The human breast cancer cell line MCF-7 and the nonmalignant breast cell line MCF-10A were obtained from ATCC;
human leukemia cell lines Reh and RS4 were originally obtained
from ATCC and generously provided by Dr. Terzah Horton,
Baylor College of Medicine. Cell line authentication was
performed by PCR amplification of nine short tandem repeat
(STR) loci (Research Animal Diagnostic Laboratory, St. Louis,
MO) and comparing the profile to the ATCC STR database. The
STR profile of MCF-7 and RS4 cell lines were identical to the
ATCC profile. The Reh cell line matched all alleles in the ATCC
Reh profile plus one extra allele at two loci.

A primary lymphoblastic leukemia specimen was transplanted
by IV injection into sub-lethally irradiated immune deficient
NOD/SCID/IL2Rg mice. When the tumor burden was established in the bone marrow (day 17), animals received treatment
with thiaminase 2000 units/kg on days 17, 20 and 24, administered by subcutaneous injection (the longer interval between
treatments in these mice in comparison to the Crl:NU-Foxn1 nude
mice was due to tolerability). The animals were sacrificed on day
33 and marrow cells were isolated and examined by flow
cytometry using human-specific antibodies for CD45 and CD19
to determine the level of human leukemia cell engraftment as
previously described [9].

Cytotoxicity assays
Human leukemia cell lines Reh or RS4 were plated in triplicate
in 96-well microtiter plates in RPMI-1640 (with 25 mM HEPES)
medium containing 10% fetal bovine serum at final densities of
86104 cells/well. MCF-7 cells were plated in the same medium at
the final density of 1000cells/well. Medium containing native
thiaminase at a concentration range of 161026 to 4 units/ml was
added to cells and incubated for four days. Following incubation,
an MTT Cell Proliferation Assay (ATCC) was performed
according to the ATCC protocol. The IC50 was calculated from
the dose response curve as the concentration of drug producing a
50% decrease in the mean absorbance compared to the untreated
wells using Prism GraphPad software. The cytotoxicity experiments were repeated a minimum of three times in triplicate.
Analysis of primary human ALL specimens was performed by
plating cells at a density of 16106/ml and treating for 24 hours
with the indicated concentration of thiaminase. Viability was
evaluated by dead cell exclusion labeling with trypan blue dye, as
PLOS ONE | www.plosone.org

Mitochondrial bioenergetics measurements
Oxygen consumption was determined using the Seahorse
Extracellular Flux (XF-96) analyzer (Seahorse Bioscience, Chicopee, MA). The XF-96 measures the concentration of oxygen and
free protons in the medium above a monolayer of cells in realtime. Thus, the rates of oxygen consumption and proton
production can be measured across several samples at a time.
To allow comparison between experiments, data are presented as
oxygen consumption rate (OCR) in pMoles/min/104 cells and the
extracellular acidification rate (ECAR) in mpH/min/104 cells.
RS4 and Reh leukemia cells were seeded at 125,000 cells/well into
gelatin-coated Seahorse Bioscience XF microplates, cultured in
the presence or absence of 2 g/L D-glucose, and then centrifuged
to adhere to the bottom of the wells, while for the MCF-7 and
MCF-10A about 45,000 cells were plated and allowed to adhere
overnight. OCR was measured four times and plotted as a
2
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Figure 1. In vivo evidence of thiaminase anticancer activity. A. A Kaplan-Meyer plot of time to pre-defined tumor volume endpoint for
subcutaneous MCF-7 breast cancer xenografts treated with thiaminase 2000 units SC QOD or buffer control. The median time to endpoint was 41
days for untreated control and 59 days (p = 0.03 Log rank test). B. A Kaplan-Meyer plot of time to pre-defined tumor volume endpoint for
subcutaneous RS4 leukemia subcutaneous xenografts treated with thiaminase 850 units SC BIW or buffer control. The median time to endpoint was
16.5 days for the control group and not reached after 60 days of observation in the treated group (p,0.001 Log rank test). C. Primary ALL and AML
specimens were thawed and plated in triplicate in two concentrations of thiaminase 0.4 units/ml and 4 units/ml, and assessed for viability at
48 hours relative to untreated cells. The ALL specimen with the asterisk was used for the in vivo study shown in Figure 1D. D. Primary ALL cells were
injected IV on Day 1; three thiaminase treatments of 2000 units/kg SC were administered on days 17, 20 and 24. The animals were sacrificed on Day
33 and bone marrow was examined by flow cytometry for human ALL cells (percent human CD45); Untreated n = 4; vehicle treated n = 10, native
thiaminase n = 8 (* p,0.01, Mann-Whitney test).
doi:10.1371/journal.pone.0085702.g001

incubation in thiaminase for 24 hrs (T-24); control for 48 hours
(C-48); thiaminase for 48 hrs (T-48); rapamycin for 48 hrs (R-48);
and both rapamycin and thiaminase for 48 hrs (R+T-48). Four
independent samples were produced for each time point for each
cell line, and cell pellets were stored at 280uC until the separate
experiments were all completed. Metabolomic studies were
performed at Metabolon, Inc. (Durham, NC). The non-targeted
metabolic profiling platform consisted of three independent
instrumental methods: ultrahigh performance liquid chromatography/tandem mass spectrometry (UHPLC/MS/MS2) optimized
for basic species; UHPLC/MS/MS2 optimized for acidic species;
and gas chromatography/mass spectrometry (GC/MS). The
detailed process of the platform; including sample processing,
instrument configuration, data acquisition, as well as metabolite
identification and quantitation, were published previously [10,11].
Three hundred and forty two metabolites were identified by
automated comparison of the ion features in the experimental
samples to a reference library of chemical standard entries that
included retention time, molecular weight (m/z), preferred
adducts, in-source fragments and associated MS spectra [12].
Instrument variability was determined by calculating the median

function of cells under the basal condition followed by the
sequential addition of oligomycin (1 mg/ml), FCCP (1 mM) and
rotonone (1 mM). The ATP-linked OCR was calculated as the
basal OCR minus the OCR measured after the addition of
oligomycin. The OCR maximal capacity was the direct rate
measured after the addition of FCCP. The reserve capacity is the
FCCP OCR minus the basal OCR. For the ECAR measurements,
cells were washed following overnight incubation and changed to
assay media lacking glucose. Basal ECAR were measured four
times and plotted as a function of cells under the basal condition
followed by the sequential addition of glucose (25 mM), oligomycin (1 mg/ml) and 2-deoxyglucose (25 mM). The rate of glycolysis
was determined by subtracting the basal ECAR from the ECAR
after the addition of glucose. Glycolytic reserve was determined by
subtracting the ECAR following the addition of oligomycin from
the ECAR following the addition of glucose. Differences between
treatment groups were calculated using the Kruskal Wallis test.

Metabolomic studies
RS4 leukemia cells and MCF-7 breast cancer cells were
analyzed under six conditions: control for 24 hrs (C-24);
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Figure 2. Effect of thiamine antagonists on thiaminase activity. A. Growth inhibition of Reh and RS4 leukemia cells in the presence or
absence of thiaminase and either N3PT or oxythiamine. B. Growth inhibition of RS4 and Reh leukemia cells incubated in normal medium, thiaminefree medium or medium containing thiaminase prior to exposure to different concentrations of N3PT. C. RS4 subcutaneous xenografts showing
untreated control, N3PT alone, 1k-PEGylated thiaminase and 1k-PEGylated thiaminase followed by N3PT. The time-to-endpoint was 16.5 days for
control, 23 days for N3PT, 25 days for 1k-PEG thiaminase and 55 days for 1k-PEG thiaminase (p,0.01 Log rank test). D. Oxygen consumption rate of
RS4 cells treated with thiaminase, N3PT or thiaminase followed by N3PT (clear: control; thin-stripe: thiaminase; thick- stripe: N3PT; solid: thiaminase +
N3PT).
doi:10.1371/journal.pone.0085702.g002

antibody was added for 1 hour at room temperature. Immunoblots
were developed by use of SuperSignal West Pico chemiluminescent substrate (Thermo Scientific) according to the manufacturer’s
protocol and analyzed by FujiFilm LAS-4000 luminescent image
analyzer (Multigauge software). The primary and secondary
antibodies used in this study are listed as follows. Anti- PKM1;
anti-BCAT2; anti-TPK1 and anti-THTPA antibodies were
purchased from Proteintech Group, Inc. (Chicago, IL). AntiPKM2 and anti-CPT1A antibodies were from Cell Signaling
Technology (Danvers, MA). Anti-BCKDE1 and anti-phosphoBCKDE1 antibodies were obtained from Bethyl laboratories
(Montgomery, TX). Anti-BCAT1, anti-b-actin and all secondary
antibodies were obtained from Sigma-Aldrich (St. Louis, MO).

relative standard deviation (RSD) for the internal standards that
were added to each sample prior to injection into the mass
spectrometers. Overall process variability was determined by
calculating the median RSD for all endogenous metabolites (i.e.,
non-instrument standards) present in 100% of a set of technical
replicates of pooled samples. Values for instrument and process
variability meet Metabolon’s acceptance criteria with instrument
variability of 3% and overall process variability of 12%. Following
normalization to total protein (Bradford assay), log transformation
and imputation with minimum observed values for each
compound, Welch’s two-sample t-tests were used to identify
biochemicals that differed significantly between experimental
groups. The entire metabolomic data sets for RS4 and MCF-7
cells, with statistical results, are included in data tables (Table S1).

Results
Immunoblot analysis

Evidence of antitumor activity of thiaminase in leukemia and
breast cancer tumor models is shown in Figure 1. Figure 1A is a
Kaplan-Meier plot of MCF-7 subcutaneous xenografts treated
with thiaminase, showing a prolongation in the time to endpoint
(pre-defined tumor volume) (TTE) from 41 days in the mock
treated cohort to 59 days in the treated cohort (p = 0.03). In Figure
1B RS4 subcutaneous xenografts show an increase in median TTE
from 16.5 days from the start of treatment to undefined TTE after
60 days (p,0.001). We have also previously shown evidence of
thiaminase activity against MDA231 breast cancer [8]. In Figure

Cells were treated with thiaminase (0.001 U/ml) and/or
rapamycin (0.1 mM) for 96 hours. Cells were lysed with a tripledetergent lysis buffer (50 mM Tris pH8.0, 150 mM NaCl, 1% NP40, 0.5% DOC, 0.1% SDS, 0.02% sodium azide, 100 mg/ml
PMSF, protease inhibitors (Roche) and phosphatase inhibitors
(Thermo Scientific)). Equal amounts of protein were loaded into
each well and separated by SDS-PAGE gel, followed by transfer
onto nitrocellulose membranes. The membranes were blocked,
incubated with the indicated primary antibodies at 4uC overnight,
and the appropriate horseradish peroxidase–conjugated secondary
PLOS ONE | www.plosone.org
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Figure 3. OCR and ECAR of leukemia and breast cell lines incubated for 48 hours in thiaminase, rapamycin or both drugs combined
(clear: control; thin-stripe: thiaminase; thick- stripe: rapamycin; solid: thiaminase + rapamycin). A. Quantification of OCR parameters. The
ATP-linked rate is the basal rate minus the rate measured after the addition of oligomycin. The maximal capacity is the rate measured after the
addition of FCCP. The reserve capacity is the basal rate minus the FCCP rate. All data are the mean 6 SEM, of triplicate samples and are representative
of 3 independent experiments ({p,0.05, *p,0.01 two way ANOVA (Newman Kruskal Wallis test). B. Quantification of ECAR parameters. Glycolysis is
the rate determine from subtracting the basal rate from the rate after the addition of glucose. Glycolytic reserve is the rate determined by subtracting
the rate following the addition of oligomycin from the rate following the addition of glucose. All data are the mean 6 SEM, of triplicate samples and
are representative of 3 ({p,0.05, *p,0.01 two way ANOVA (Newman Kruskal Wallis test).
doi:10.1371/journal.pone.0085702.g003

further detailed examination of the metabolic effects of thiaminase
in the breast cancer cell line MCF-7 and in the RS4 leukemia cell
line. In addition, for further points of comparison, we included
selected studies in two additional cell lines, Reh leukemia cells,
another lymphoblastic leukemia cell line, and MCF-10A, a nonmalignant breast cell line.
The studies in Figure 1, along with previous reports, demonstrate that the enzyme thiaminase has activity against breast and
lymphoid leukemia cell lines. To first determine whether the

1C, the activity of thiaminase is shown against primary human
leukemia cells. The most sensitive primary leukemia specimens
appear to be lymphoblastic specimens with MLL-gene rearrangements. This was of interest as the RS4 cell line is also an
MLL-rearranged cell line. Figure 1D shows flow cytometric
analysis of bone marrow of a primary MLL-rearranged leukemia
cell xenograft treated with thiaminase demonstrating a decrease in
leukemia cell proportion after treatment. These studies, along with
previous studies [7,8], provided the rationale for performing
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Figure 4. Validation of thiaminase action in of RS4 leukemia cells and MCF-7 breast cancer cells by metabolomic analysis. Both cell
lines were analyzed under six conditions: control for 24 hours (C-24); incubation in thiaminase for 24 hours (T-24); control for 48 hours (C-48);
thiaminase for 48 hours (T-48); rapamycin for 48 hours (R-48); and both rapamycin and thiaminase for 48 hours (R+T-48). The median is indicated by
the bar in the center of the rectangle, the rectangle dimensions reflect the range of the two mid-quartile values, and the outer bars represent the
ranges of all of the values. The data represent four independent experiments. For C-48 vs T-48 and C-48 vs T+R-48 comparisons, ** indicates p,0.05
and * indicates 0.05,p,0.1). A. Internal validation in RS4 cells, showing the expected decrease in thiamine and thiamine diphosphate in thiaminase
treated cells, an increase in thiazole, the product of thiaminase cleavage of thiamine in the thiaminase-treated cells and the appearance of rapamycin
only in the rapamycin treated cells. B. Validation of thiaminase-mediated inhibition of transketolase by demonstration of the accumulation of
substrate surrogates ribose and ribulose in both RS4 and MCF-7 cell lines at 48 hours. C. Immunoblot analysis of thiamine pyrophosphate kinase
(TPK1) and thiamine triphosphatase (THTPA) in RS4 and MCF-7 cells treated with thiaminase, rapamycin or both. D. Immunoblot analysis of pyruvate
kinase isozymes M1 and M2 and carnitine palmitoyl transferase (CPT1) in RS4 and MCF-7 cells treated with thiaminase, rapamycin or both.
doi:10.1371/journal.pone.0085702.g004

activity of thiaminase was related to thiamine depletion, we
explored the ability of small molecule thiamine antagonists to
potentiate the cytotoxicity of thiaminase. We screened thiamine
analogs pyrithiamine, oxythiamine and N3’ pyridylthiamine
(N3PT) [13,14] for activity as inhibitors of thiaminase and
substrates of thiaminase. We found that oxythiamine and N3PT
were thiaminase inhibitors, and that pyrithiamine was a thiaminase substrate (data not shown). Therefore we hypothesized that
oxythiamine and N3PT would reverse thiaminase toxicity if given
simultaneous with thiaminase (because they would inhibit enzyme
activity) but would act synergistically if given in sequence (because
cells deprived of thiamine would become sensitive to small
molecule thiamine antagonists due to TDE apoenzyme formation
during thiamine starvation). In Figure 2A, simultaneous incubation of thiaminase and thiamine antagonists inhibits thiaminase
activity, while in Figure 2B, sequential administration of thiaminase followed by N3PT demonstrates synergistic cytotoxicity.
Importantly, the effect of pre-incubation in thiaminase is similar to
the effect of pre-incubation in thiamine-free medium, indicating
that TDE apoenzyme formation is required for the cytotoxicity of
small molecule TDE inhibitors, and also demonstrating that
extracellular thiamine starvation is sufficient to make small
molecule TDE inhibitors cytotoxic. In order to further examine
the interplay of N3PT and thiaminase in an in vivo model, we
administered PEGylated thiaminase in sequence with N3PT,
choosing PEGylated enzyme over the native enzyme shown in
Figure 1B to be able to separate extracellular thiamine deprivation
caused by PEGylated thiaminase from the intracellular effect of
N3PT [6]. In Figure 2C, the RS4 xenograft experiment shows that
sequential administration of PEGylated thiaminase followed by
N3PT produced an increased median TTE (55 days) compared to
the untreated control (16.5 days), PEG-thiaminase (25 days) or
N3PT (23 days) alone (p,0.01), confirming the in vitro data.
Since thiaminase should inhibit two key TDEs involved in
Krebs cycle metabolism, pyruvate dehydrogenase complex and 2oxoglutarate dehydrogenase (2-OGDH, aka alpha-ketoglutarate
dehydrogenase), we examined respiration (as oxygen consumption
rate; OCR) and the rate of extracellular acidification (a measure of
lactate production; ECAR) in leukemia and breast cancer cell
lines. In Figure 2D, the oxygen consumption rate is decreased in
an additive fashion with the sequential administration of
thiaminase followed by N3PT, showing further evidence of
interaction of thiaminase and a small molecule thiamine antagonist. In addition, since rapamycin reversed thiaminase-mediated
growth inhibition in leukemia cell lines [7] but not breast cancer
cell lines (data not shown), we examined the effect of rapamycin
alone and in combination with thiaminase. In Figure 3A,
thiaminase consistently decreased OCR in two lymphoid leukemia
cell lines RS4 and Reh, in the breast cancer cell line MCF-7 and in
the non-malignant breast cell line MCF-10A. Also, as expected,
rapamycin similarly suppressed OCR in the four cell lines.
However, adding rapamycin resulted in an inhibition of the
PLOS ONE | www.plosone.org

thiaminase-mediated decrease in OCR, rather than resulting in an
additive effect as was seen with N3PT in Figure 2B.
Similarly, thiaminase increased ECAR in the two breast cell
lines: the MCF-7 cell line and the MCF-10A cell line (Figure 3B).
Although rapamycin alone did not have a significant effect on
ECAR, the addition of rapamycin to thiaminase once again
blunted the effect of thiaminase in all four cell lines. The consistent
inhibition of thiaminase effect on OCR and ECAR by rapamycin
in all four cell lines demonstrates a previously unidentified activity
of mTOR inhibition in relation to TDEs. However, the
observation that the rapamycin has similar effects on the leukemia
cell lines, where it reverses growth inhibition [7], and MCF-7 and
MCF-10A cell lines, where it has no effect on thiaminase
cytotoxicity (data not shown), suggests that the effect of thiaminase
on OCR and ECAR may not be the determinant of thiaminase
anticancer activity. To rule out the possibility that rapamycin
could directly inhibit thiaminase enzymatic activity, which could
explain the reversal of the effects of thiaminase by rapamycin, we
directly examined the ability of rapamycin to inhibit thiaminase
enzyme activity and found no evidence that rapamycin was a
thiaminase enzyme inhibitor (data not shown).
To further understand how thiaminase alters cellular metabolism, and how rapamycin reverses thiaminase effects, we
undertook a metabolomic analysis of RS4 leukemia cells and
MCF-7 breast cancer cells exposed to thiaminase, rapamycin or
both. Figure 4A shows internal validation of the effects of
thiaminase in RS4 cells. As expected, the levels of thiamine and
thiamine diphosphate were decreased in the thiaminase treated
conditions, and thiazole (a catabolic product of thiaminase
cleavage of thiamine) is increased in the thiaminase treated cells,
confirming the finding that rapamycin does not interfere with the
enzymatic activity of thiaminase. In fact, thiamine was below the
limit of detection in thiaminase treated cells in the absence of
rapamycin. Also, rapamycin was detected only in the rapamycintreated cells. Evidence for inhibition of the TDE transketolase was
observed with significant increases in ribose and ribulose,
surrogates for transketolase substrates ribose 5-phosphate and
ribulose 5-phosphate respectively, in both RS4 and MCF-7 cells
(Figure 4B). These results demonstrate a common signature of
transketolase inhibition in the two cell lines. Furthermore, the
accumulation is partly to completely reversed by rapamycin,
demonstrating an antagonistic effect of rapamycin on thiamineinduced transketolase inhibition in addition to its antagonistic
effects on OCR and ECAR.
Although there was no evidence that rapamycin altered the level
of thiaminase-induced thiamine depletion, we sought to confirm
this observation by examining the expression of enzymes that
regulate thiamine phosphorylation. In Figure 4C the expression of
both thiamine pyrophosphokinase TPK1, an enzyme that
phosphorylates thiamine and thiamine monophosphate into its
active diphosphate form, and thiamine triphosphatase (THTPA),
an enzyme that dephosphorylates intracellular thiamine triphos7
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Figure 5 Differential effects of thiaminase on branched chain amino acid catabolism. A. Schematic diagram showing branched chain
amino acid catabolism. B. Different metabolomic signatures indicating inhibition of BCKDH by thiaminase. The top three panels show accumulation
of BCKDH substrates after 48 hours of thiaminase treatment in RS4 leukemia cells and the reversal of this accumulation by rapamycin, while the lower
three panels show a decrease in BCKDH products in MCF-7 cells after thiaminase treatment- most notably isovalerylcarnitine, which is also reversed
by rapamycin. C. An immunoblot of cytosolic and mitochondrial branched chain amino acid transferase (cBCAT and mBCAT), the enzymes that
catalyzes the reactions that produce BCKDH substrates, and total and phosphorylated BCKDH subunit E1 (BCKD-E1 and pBCKD-E1, respectively) in
RS4 leukemia cells treated with thiaminase, rapamycin or both. For C-48 vs T-48 and C-48 vs T+R-48 comparisons, ** indicates p,0.05 and * indicates
0.05,p,0.1). D. Cytotoxicity assay of RS4 and MCF-7 cells treated with increasing concentrations of thiaminase (in milliunits, mu) under control
conditions or in medium that contains gabapentin.
doi:10.1371/journal.pone.0085702.g005

phate into the active diphosphate form, are shown. A modest
increase in THTPA expression is seen in RS4 cells treated with
both thiaminase and rapamycin, which may be a result of
feedback from intracellular thiamine diphosphate depletion, but
no other changes are seen in either RS4 or MCF-7 cells. In Figure
4D, the expression of enzymes involved in energy metabolism,
pyruvate kinase isoforms M1 and M2, and carnitine palmitoyl
transferase 1 (CPT1A) were also examined by immunoblot. PKM1 expression was decreased in MCF-7 cells relative to RS4 cells.
In MCF-7 cells, both PK-M2 and CPT1A expression levels were
modestly reduced by rapamycin, and this suppression was reversed
by thiaminase in the case of CPT1A but not PK-M2. However,
similar findings were not observed in RS4 cell lines, adding more
evidence to the overall observation that different cell lines will
respond differently to acute thiamine depletion.
Figure 5 shows effects of thiaminase on the TDE branchedchain keto acid dehydrogenase (BCKDH), and demonstrates
different metabolomic signatures between RS4 leukemia cells and
MCF-7 breast cancer cells. In Figure 5A the metabolic pathways
for the catabolism of branched chain amino acids is illustrated.
The metabolomic profile for these metabolites is shown in Figure
5B and Figure S1. In RS4 cells, thiaminase increases the levels
of BCKDH substrates alpha-hydroxyisocaproate, 2-hydroxy-3methylvalerate and alpha-hydroxyisovalerate, all metabolites that
are increased in maple syrup urine disease, the congenital form of
BCKDH deficiency. In contrast, a decrease in the products of
BCKDH are observed in MCF-7 cells, with decreased isobutyrylcarnitine, 2-methybutyrylcarnintine and isovalerylcarnitine.
Once again the effects of thiaminase were offset by rapamycin.
These findings suggest that the substrate load for BCKDH is much
higher in RS4 leukemia cells. Therefore, we investigated the
expression of the cytosolic form and the mitochondrial form of the
branched chain aminotransferases, cBCAT and mBCAT - the
enzymes immediately upstream of BCKDH, in both RS4 and
MCF-7 cells. As shown in Figure 5C, MCF-7 cells do not appear
to express cBCAT, providing a potential explanation for the lack
of BCKDH substrate accumulation in this cell line after
thiaminase treatment. Figure 5C also appears to show an apparent
increase in phosphorylated BCKD-E1 after thiaminase treatment
in MCF-7 cells which is reversed by co-treatment with rapamycin.
Phosphorylation of BCKDH inactivates the enzyme and may
contribute to the decrease of BCKDH products seen in the MCF-7
cells, and suggests that there may be an interaction between
thiaminase, rapamycin and the enzymes that regulate BCKDH
phosphorylation. To determine whether the accumulation of
BCKDH substrates contributed to thiaminase-induced growth
inhibition in RS4 cells, we examined thiaminase growth inhibition
in the presence of gabapentin, a structural analog of leucine and
an inhibitor of cBCAT [15]. As shown in Figure 5D, gabapentin
partially protected RS4 cells from thiaminase growth inhibition
while having no effect on MCF-7 cells.
Thiaminase also affected the catabolism of aromatic amino
acids in RS4 leukemia cells. As shown in Figure 6A, the
breakdown products of both phenylalanine (phenylpyruvate and
PLOS ONE | www.plosone.org

phenyllactate) and tyrosine (4-hydroxyphenylpyruvate (HPP) and
3-(4-hydroxyphenyl)lactate (HPLA)) are increased in the thiaminase treated cells. Furthermore, as shown in Figure 6B, tryptophan
catabolites are increased through one pathway which produces
indolelactate, but not through the kynurenine pathway. As in the
approach we took with the alteration of branched chain amino
acids, we examined the possibility that the accumulation of these
aromatic amino acid catabolites mediated the growth inhibitory
effects of thiaminase. The drug nitisinone, which inhibits 4hydroxyphenylpyruvate dioxygenase, an enzyme that catalyzes an
alternative catabolic pathway for phenylalanine [16] and would be
expected to increase the accumulation of aromatic amino acid
catabolities, did not however alter the dose-response curves of
thiaminase in either cell line (data not shown).

Discussion
Any systematic difference between cancer cells and normal cells
provides a potentially exploitable therapeutic opportunity. The
altered energy metabolism in cancer cells, known as the Warburg
effect, represents such an opportunity. The vitamin thiamine is a
key cofactor in two critical enzymes in energy metabolism: PDH
and 2-OGDH. It is also a cofactor for two other critical enzymes;
TK, which is required for the formation of the biomass of a cell
through the pentose phosphate shunt; and BCKDH which
regulates the catalysis of branched chain amino acids.
Thiamine requires active transport for cellular uptake. We have
previously shown down-regulation of thiamine transporters in
human tumors [2,3], suggesting that tumors may have a
nutritional vulnerability that could be exploited clinically, analogous to the down-regulation of asparagine synthase in acute
lymphoblastic leukemia which is exploited therapeutically by the
bacterial enzyme asparaginase. The enzyme thiaminase catalyzes
the cleavage of thiamine into two molecules: one is a pyrimidine
(conjugated to a nucleophile for type I thiaminases) and the other
is a thiazole that may be phosphorylated, depending on the
thiamine substrate that enters the reaction [5]. Several forms of
thiaminase exist in nature, including plant, animal and bacterial
forms of the enzyme, thus serving as an example of convergent
evolution even though the physiologic role of an enzyme that
destroys an essential nutrient is not clear. We have developed
methods to produce, purify and modify Bacillus thiaminolyticus
thiaminase I enzyme and have shown in preclinical xenograft
models that therapy directed at thiamine dependent enzymes
(TDEs), a completely novel concept and strategy, has the potential
to treat leukemia [7]and breast cancer [8], and despite its antimetabolite role, thiaminase can cause tumor responses at a
systemically tolerable dose.
To determine which TDE is responsible for the cytotoxic effects
of thiaminase we examined the effect of the enzyme on cellular
respiration and metabolism with the goal of identifying the critical
TDEs responsible for cytotoxicity in the setting of acute thiamine
deprivation. Since thiaminase is a bacterial enzyme, it is less-thanideal as a pharmaceutical product and the identification of the
9
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Figure 6. Effects of thiaminase on aromatic amino acid catabolism. A. Accumulation of the products of phenylalanine (phenylpyruvate and
phenyllactate) and tyrosine (hydroxyphenylpyruvate and hydroxyphenyllactate) catabolism in RS4 cells after treatment with thiaminase for 48 hours.
B. Accumulation of tryptophan catabolites after thiaminase treatment, showing accumulation of indolelactate but not kynurenine. For C-48 vs T-48
and C-48 vs T+R-48 comparisons, ** indicates p,0.05 and * indicates 0.05,p,0.1).
doi:10.1371/journal.pone.0085702.g006

specific pathway disrupted by thiamine deprivation that leads to
cytotoxicity could reveal an alternative pharmacologic approach.
The metabolomic changes in the global biochemical profiles of
RS4 leukemia cells and MCF-7 breast cancer cells treated with
thiaminase are consistent with inhibition of BCKDH complex,
pyruvate dehydrogenase complex, and transketolase inhibition.
However, inhibition of the same enzyme was shown to result in
different metabolic consequences in the case of BCKDH, where
inhibition in RS4 cells caused a demonstrable increase in BCKDH
substrates, whereas in MCF-7 cells inhibition led to a decrease in
the products of the enzymatic reaction. This difference may then
lead to different consequences on cell growth, as the substrates for
BCKDH are known to be toxic metabolites and result in the organ
toxicity in the metabolic syndrome maple syrup urine disease. We
have previously shown that RS4 cells, as well as other lymphoid
leukemia cell lines, have a biphasic dose response to thiaminase,
where there is an initial growth inhibition related to extracellular
thiamine depletion and a cytotoxic response at higher concentrations related to intracellular thiamine depletion [7]. Gabapentin
appears to be protective against the growth inhibitory effects of
thiaminase in RS4 cells at the concentrations that produce
extracellular thiamine depletion, indicating that growth inhibition
is not due solely to thiamine depletion but also to the accumulation
of branched-chain amino acid catabolites. These studies demonstrate that the cell lines, and presumable tumors, have different
metabolic consequences resulting from inhibition of the same
enzymes, and that these consequences may form the basis of
sensitivity to TDE inhibition as well as identify potential
biomarkers of response.
In addition, thiaminase treatment was associated with increased
lipolysis and decreased polyamine synthesis (data not shown), both
of which were reversed by co-treatment with rapamycin. These
changes are consistent with altered energy production and reduced
cellular proliferation as a result of thiamine depletion, but also may
be related to our previous observation that mammary tumor
formation is delayed in mice fed a low-thiamine normal-fat diet
but not in mice fed a low-thiamine high-fat diet [4]. Although fatty
acid metabolism may be affected by inhibition of 2-hydroxyl-CoA
lyase (HACL1), a peroxisomal enzyme that also requires thiamine
pyrophosphate as a cofactor and mediates the catabolism of
branched chain fatty acids and 2-hydroxyl straight chain fatty
acids [17], we did not see any evidence for accumulation of these
metabolites in either cell line.

production, biomass generation and amino acid catabolism.
Comparison of the changes observed with thiaminase treatment
in RS4 cells versus MCF-7 cells reveals different biochemical
signatures as a result of thiamine depletion that may reflect
differences in the relative contributions of different pathways to
energy production and anaplerotic contributions to the TCA
cycle. The near-global reversal of the specific metabolic effects of
thiaminase by rapamycin indicate a closer regulation of thiaminedependent metabolism by mTOR than has been previously
appreciated, and further studies are needed to determine how
mTOR signaling pathways regulates thiamine-dependent metabolism. The disruption of thiamine metabolism results in cytotoxicity in breast cancer and leukemia tumor model systems, and has
the potential to provide novel targets for therapies directed toward
these malignancies.

Supporting Information
Figure S1 Results of metabolomic analysis for
branched-chain amino acid metabolites in A.) RS4 cell
line and B.) MCF7 cell cline analyzed under six conditions:
control for 24 hours (C-24); incubation in thiaminase for 24 hours
(T-24); control for 48 hours (C-48); thiaminase for 48 hours (T48); rapamycin for 48 hours (R-48); and both rapamycin and
thiaminase for 48 hours (R+T-48). The median is indicated by the
bar in the center of the rectangle, the rectangle dimensions reflect
the range of the two mid-quartile values, and the outer bars
represent the ranges of all of the values. The data represent four
independent experiments. For C-48 vs T-48 and C-48 vs T+R-48
comparisons, ** indicates p,0.05 and * indicates 0.05,p,0.1).
(TIF)
Table S1 Metabolomic pathway heat map data for RS4
and MCF-7 cells treated with thiaminase (T), rapamycin
(R), or both (R+T) for 24 and 48 hours.
(XLSX)

Acknowledgments
The authors thank the Research Communication Office of the Markey
Cancer Center at the University of Kentucky for editorial and graphics
assistance. This work was supported by DanceBlue, an effort of the
University of Kentucky student community to support pediatric oncology
care and research.

Author Contributions

Conclusions

Conceived and designed the experiments: MAK CTJ DKS JAM.
Performed the experiments: SL SM MAK CTJ CW. Analyzed the data:
MAK DKS JAM. Contributed reagents/materials/analysis tools: SM
MAK CTJ CW DKS JAM. Wrote the paper: MAK CTJ JAM.

Overall these studies demonstrate that TDE disruption leads to
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